Delcath Systems Inc DCTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
-
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
-
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
-
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
-
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
-
Delcath Systems to Host First Quarter 2026 Earnings Call
Trading Information
- Previous Close Price
- $12.81
- Day Range
- $12.43–12.79
- 52-Week Range
- $8.12–13.71
- Bid/Ask
- $12.44 / $12.51
- Shares Outstanding
- 34.52M
- Market Cap
- $431.18M
- Volume/Avg
- 27,832 / 473,127
Key Statistics
- Price/Earnings (Normalized)
- 1,281.00
- Price/Sales
- 5.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 1.93%
Company Profile
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 156
- Website
- https://www.delcath.com
Valuation
|
Metric
|
DCTH
|
|---|---|
Price/Earnings (Normalized) | 1,281.00 |
Price/Book Value | 3.92 |
Price/Sales | 5.53 |
Price/Cash Flow | 23.31 |
Price/Earnings
DCTH
Financial Strength
|
Metric
|
DCTH
|
|---|---|
Quick Ratio | 9.77 |
Current Ratio | 11.24 |
Interest Coverage | — |
Quick Ratio
DCTH
Profitability
|
Metric
|
DCTH
|
|---|---|
Return on Assets (Normalized) | 15.76% |
Return on Equity (Normalized) | 17.36% |
Return on Invested Capital (Normalized) | 14.89% |
Return on Assets
DCTH
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|!!mN^Yv | LOCK|cQ$WS | $175B | |||
| Stryker Corp
SYK
| LOCK|G!>J&@w | LOCK|$@l | $123B | |||
| Medtronic PLC
MDT
| LOCK|#d&%#F | LOCK|%%$V? | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|#d>Rm!P | LOCK|Jxk^s | $65B | |||
| Edwards Lifesciences Corp
EW
| LOCK|$q!bfN?@ | LOCK|gj$<? | $49B | |||
| DexCom Inc
DXCM
| LOCK|&rr!$FXr | LOCK|FGDv^ | $30B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|?^%gnsD | LOCK|z? | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|@?P | LOCK|RV> | $26B | |||
| Steris PLC
STE
| LOCK|N>pvRn? | LOCK|Xg&^ | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|&%JhfD@ | LOCK|mvl | $18B |
United States